Coronary heart disease (CHD) is the leading cause of global morbidity and mortality, yet no comprehensive evaluation of its global economic costs exists. A systematic review was conducted with meta-analysis to examine the costs of CHD treatment by region and CHD subtypes, examining whether there are cost differences by sex, and examining costing methodologies.
This review illustrated the expense associated with CHD, which is varied by region and CHD subtypes. The observed cost difference by sex warrants further exploration of sex-specific factors influencing cost disparities. Exploring advanced costing methods such as time-driven activity-based costing can optimise resource allocation and identify opportunities to reduce unnecessary costs and cost disparities.
|
|